The 2026 GU ASCO annual meeting featured a urothelial carcinoma session and a discussant presentation by Dr. Tyler F. Stewart ...

Detailed price information for Alx Oncology Holdings Inc (ALXO-Q) from The Globe and Mail including charting and trades.

This marks the first time a bispecific ADC has demonstrated a dual benefit in both PFS and OS within a phase 3 trial for TNBC ...

EMA validates Type II Variation marketing application for Enhertu as post-neoadjuvant treatment for patients with HER2 positive earlybreast cancer: Tokyo Saturday, February 21, 20 ...

The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU ® (trastuzumab deruxtecan) as a monotherapy for adult patients with HER2 ...

CHENGDU, China, Feb. 6, 2026 /PRNewswire/ — Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that a new indication application for its ...

Based on DESTINY-Breast05 phase 3 trial results, which showed ENHERTU reduced the risk of invasive disease recurrence or death by 53% compared to T-DM1 If approved, Daiichi Sankyo and AstraZeneca's ...

Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.0 This guideline consolidates all previous updates and reflects the body of evidence informing ...

Dual anti–human epidermal growth factor receptor 2 (HER2) therapy plus chemotherapy followed by maintenance treatment with HER2-targeted and endocrine therapies is standard first-line treatment for ...

The MarketWatch News Department was not involved in the creation of this content. -- Phase 1b study to evaluate combination of zongertinib and zanidatamab in HER2-positive breast cancer patients ...

Experts discuss the critical unmet needs in HER2-mutant non-small cell lung cancer, highlighting disparities in testing and treatment access. In this episode, panelists identify ongoing challenges in ...